Evolution of fibrinolysis status with D-dimer level and the rate of plasminogen activator inhibitor type-1/D-dimer in acute coronary syndrome patients complicated with impaired glucose tolerance

OBJECTIVE: To study the status of fibrinolytic inhibition in patients with acute coronary syndrome (ACS) complicated with impaired glucose tolerance (IGT) and to evaluate the effect of fibrinolytic inhibition on treatment and prognosis

Bibliographische Detailangaben
Veröffentlicht in:Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue. - 1998. - 15(2003), 8 vom: 15. Aug., Seite 472-5
1. Verfasser: Wu, Wo-dong (VerfasserIn)
Weitere Verfasser: Xu, Yun-hong, Tan, Pei-yi
Format: Aufsatz
Sprache:Chinese
Veröffentlicht: 2003
Zugriff auf das übergeordnete Werk:Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
Schlagworte:English Abstract Journal Article Research Support, Non-U.S. Gov't Blood Glucose Fibrin Fibrinogen Degradation Products Fibrinolytic Agents Plasminogen Activator Inhibitor 1 SERPINE1 protein, human fibrin fragment D PLAT protein, human mehr... EC 3.4.21.68 Tissue Plasminogen Activator
LEADER 01000caa a22002652 4500
001 NLM126724083
003 DE-627
005 20250204053102.0
007 tu
008 231222s2003 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0423.xml 
035 |a (DE-627)NLM126724083 
035 |a (NLM)12919647 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Wu, Wo-dong  |e verfasserin  |4 aut 
245 1 0 |a Evolution of fibrinolysis status with D-dimer level and the rate of plasminogen activator inhibitor type-1/D-dimer in acute coronary syndrome patients complicated with impaired glucose tolerance 
264 1 |c 2003 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 24.03.2016 
500 |a Date Revised 15.08.2003 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: To study the status of fibrinolytic inhibition in patients with acute coronary syndrome (ACS) complicated with impaired glucose tolerance (IGT) and to evaluate the effect of fibrinolytic inhibition on treatment and prognosis 
520 |a METHODS: The subjects were divided into three groups included 39 patients with ACS without diabetes mellitus, 37 patients with IGT+ACS and 36 patients with ACS+noninsulin-dependent diabetes mellitus (NIDDM). Twenty healthy people were randomized to be control group. The plasma levels of tissue type plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-1) and plasma D-dimer were detected by enzyme linked immunoadsorbent assay (ELISA) technique. The index of status of fibrinolysis was detected with the plasma levels of PAI-1, D-dimer and the ratio of PAI-1/D-dimer. This index was used to evaluate the status of fibrinolytic inhibition and the clinical out come in patients with AMI 
520 |a RESULTS: Plasma level of PAI-1 was significantly higher in IGT+ACS patients and NIDDM +ACS patients than that in ACS(P<0.05), but the plasma level of D-dimer raised from basic level was significantly lower in IGT+ ACS patients and NIDDM+ACS patients than that in ACS (P<0.05). The ratio of PAI-1/D-dimer was significantly higher in IGT+ACS patients and NIDDM +ACS patients than that in ACS or in control group (P<0.01). For AMI patients in treatment groups, the rate of reperfusion after the thrombolytic was significantly lower and the rate of incidences in pump failure was significantly higher in IGT+ACS patients and NIDDM+ACS patients than that in ACS, too (P<0.01 and P<0.05). The incidences of serious arrhythmia, re-infarction and death were also higher in IGT+ACS patients and NIDDM +ACS patients 
520 |a CONCLUSION: The fibrinolytic inhibition is existed in IGT+ACS group patients. The plasma level of D-dimer combined with the ratio of PAI-1/D-dimer could be used to be the evidence and to be the index to evaluate the status of fibrinolytic inhibition and prognosis 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Blood Glucose  |2 NLM 
650 7 |a Fibrin Fibrinogen Degradation Products  |2 NLM 
650 7 |a Fibrinolytic Agents  |2 NLM 
650 7 |a Plasminogen Activator Inhibitor 1  |2 NLM 
650 7 |a SERPINE1 protein, human  |2 NLM 
650 7 |a fibrin fragment D  |2 NLM 
650 7 |a PLAT protein, human  |2 NLM 
650 7 |a EC 3.4.21.68  |2 NLM 
650 7 |a Tissue Plasminogen Activator  |2 NLM 
650 7 |a EC 3.4.21.68  |2 NLM 
700 1 |a Xu, Yun-hong  |e verfasserin  |4 aut 
700 1 |a Tan, Pei-yi  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue  |d 1998  |g 15(2003), 8 vom: 15. Aug., Seite 472-5  |w (DE-627)NLM098227793  |x 1003-0603  |7 nnns 
773 1 8 |g volume:15  |g year:2003  |g number:8  |g day:15  |g month:08  |g pages:472-5 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 15  |j 2003  |e 8  |b 15  |c 08  |h 472-5